Articles

Hollywood, FL—In a study presented at the 2016 annual conference of the National Comprehensive Cancer Network, a real-world assessment of lenalidomide use in the treatment of patients with myelodysplastic syndrome (MDS) showed that dose modifications had a strong positive effect on outcomes.

By Meg Barbor, MPH

Supportive Care

TOP - November 2016, Vol 9, No 4

Adelaide, Australia—Stomatitis is a dose-limiting toxicity associated with the use of mammalian target of rapamycin (mTOR) inhibitors, but new treatments can improve quality of life for patients suffering from this often debilitating condition, according to data presented at the 2016 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer.

By Phoebe Starr

Hematologic Cancers

TOP - November 2016, Vol 9, No 4

Chicago, IL—A novel compound called CPX-351 that combines 2 older drugs (cytarabine and daunorubicin) in a new drug-delivery platform improved survival among older patients with newly diagnosed, high-risk (secondary) acute myeloid leukemia (AML), according to results of a phase 3 trial presented at the American Society of Clinical Oncology 2016 Annual Meeting.

On October 18, 2016, atezolizumab (Tecentriq; Genentech), a PD-L1 inhibitor, was approved by the FDA for patients with metastatic non–small-cell lung cancer (NSCLC) associated with the EGFR or ALK genetic mutations whose disease progressed during or after treatment with platinum-containing chemotherapy.

FDA News & Updates, In the News

Web Exclusives

The US Food and Drug Administration has granted accelerated approval to pembrolizumab (Keytruda injection) for use in patients with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed after platinum-containing chemotherapy. The injection is recommended to be administered at 200 mg intravenously for 30 minutes every 3 weeks.

Multivitamin Use During Chemotherapy May Reduce Risk for Peripheral Neuropathy

By Caroline Helwick

Supportive Care

TOP - August 2016, Vol 9, No 3

Multivitamin supplement use was associated with a reduction in symptoms of chemotherapy-induced peripheral neuropathy (CIPN) in a subanalysis of the SWOG S0221 trial. Patients who were using multivitamins before chemotherapy had 40% less neuropathy, and those using them during or after treatment had a 23% reduced risk.

Price of Drugs and Affordability Don’t Always Jibe

By Phoebe Starr

Conference Correspondent

TOP - August 2016, Vol 9, No 3

A collaborative international pilot study found large differences in retail prices for 23 cancer drugs, showing highest retail prices in the United States and lowest prices in India and South Africa. Lower prices, however, did not necessarily mean the drugs were more affordable.

The New World of Biosimilars

By Meg Barbor, MPH

TOP - August 2016, Vol 9, No 3

The first oncology biosimilar—filgrastim-sndz (Zarxio)—was approved in the United States in March 2015, but this category of drugs is still fairly misunderstood, according to Jim M. Koeller, MS, Professor, College of Pharmacy, University of Texas at Austin.

Immunotherapy: Separating Facts from Fiction

Immunotherapy

TOP - August 2016, Vol 9, No 3

Response is a poor outcome measure of immunotherapy, according to Tanguy Seiwert, MD, who addressed this and other concerning issues in immunotherapy at the 2016 Multidisciplinary Head and Neck Cancer Symposium.

Articles

Page 122 of 289